Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2001 | 1 |
2020 | 1 |
2021 | 1 |
2023 | 1 |
2024 | 1 |
Search Results
4 results
Results by year
Filters applied: . Clear all
It looks like you are searching for an author.
Results are currently sorted by Best Match. To see the newest results first,
change the sort order to Most Recent.
Page 1
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
Kidney Int. 2021 Jul;100(1):225-237. doi: 10.1016/j.kint.2020.10.046. Epub 2020 Dec 8.
Kidney Int. 2021.
PMID: 33307104
Free article.
Clinical Trial.
Tislelizumab Plus Platinum and Etoposide Versus Placebo Plus Platinum and Etoposide as First-Line Treatment for Extensive-Stage SCLC (RATIONALE-312): A Multicenter, Double-Blind, Placebo-Controlled, Randomized, Phase 3 Clinical Trial.
Cheng Y, Fan Y, Zhao Y, Huang D, Li X, Zhang P, Kang M, Yang N, Zhong D, Wang Z, Yu Y, Zhang Y, Zhao J, Qin T, Chen C, Leaw S, Zheng W, Song Y; RATIONALE-312 Study Group.
Cheng Y, et al.
J Thorac Oncol. 2024 Mar 7:S1556-0864(24)00115-1. doi: 10.1016/j.jtho.2024.03.008. Online ahead of print.
J Thorac Oncol. 2024.
PMID: 38460751
Free article.
Item in Clipboard
A 1-year, placebo-controlled preservation of function survival study of donepezil in AD patients.
Mohs RC, Doody RS, Morris JC, Ieni JR, Rogers SL, Perdomo CA, Pratt RD; "312" Study Group.
Mohs RC, et al.
Neurology. 2001 Aug 14;57(3):481-8. doi: 10.1212/wnl.57.3.481.
Neurology. 2001.
PMID: 11502917
Clinical Trial.
Item in Clipboard
Corrigendum to "The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment." Kidney Int. 2021;100:225-237.
Ariceta G, Dixon BP, Kim SH, Kapur G, Mauch T, Ortiz S, Vallee M, Denker AE, Kang HG, Greenbaum LA; 312 Study Group.
Ariceta G, et al.
Kidney Int. 2023 Jul;104(1):205. doi: 10.1016/j.kint.2023.04.010.
Kidney Int. 2023.
PMID: 37349053
Free article.
No abstract available.
Item in Clipboard
Cite
Cite